Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...

After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...

US biotech IGM Biosciences (Nasdaq: IGMS), which is developing and delivering medicines to treat patients with autoimmune and ...

A notable development is the termination of IGM’s collaboration with Sanofi (NYSE:NASDAQ:SNY), which has raised concerns about the company’s partnerships and future prospects. In response to ...

The partnership with Sanofi, which focuses on IgM-based agonists targeting autoimmune and inflammatory diseases, includes three preclinical candidates with potential milestone payments exceeding ...

The end of IGM’s collaboration with Sanofi represents a significant setback. Such partnerships often provide smaller biotech firms with financial support, research and development resources, and ...

On Monday, IGM Biosciences, Inc., a pharmaceutical company based in Mountain View, California, announced the termination of a significant collaboration and license agreement with Genzyme Corporation, ...

Sanofi has agreed another deal to flesh out its R&D pipeline, paying IGM Biosciences $150 million upfront to gain access to its engineered IgM antibody technology across six targets in oncology ...

Cambridge, Massachusetts-based Vor Bio has confirmed that it will halt clinical and manufacturing operations, including its ...